Ovid Therapeutics Inc [OVID] stock is trading at $0.29, up 6.53%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The OVID shares have gain 13.18% over the last week, with a monthly amount drifted -39.62%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ovid Therapeutics Inc [NASDAQ: OVID] stock has seen the most recent analyst activity on June 18, 2024, when Oppenheimer downgraded its rating to a Perform. Previously, B. Riley Securities started tracking the stock with Buy rating on April 30, 2024, and set its price target to $9. On April 29, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $9 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $8 on April 05, 2024. BTIG Research initiated its recommendation with a Buy and recommended $11 as its price target on December 21, 2023. Oppenheimer started tracking with a Outperform rating for this stock on October 13, 2023, and assigned it a price target of $8. In a note dated April 20, 2021, Cantor Fitzgerald downgraded an Neutral rating on this stock but restated the target price of $4.
Ovid Therapeutics Inc [OVID] stock has fluctuated between $0.24 and $3.45 over the past year. Currently, Wall Street analysts expect the stock to reach $7.33 within the next 12 months. Ovid Therapeutics Inc [NASDAQ: OVID] shares were valued at $0.29 at the most recent close of the market. An investor can expect a potential return of 2427.59% based on the average OVID price forecast.
Analyzing the OVID fundamentals
Ovid Therapeutics Inc [NASDAQ:OVID] reported sales of 0.57M for the trailing twelve months, which represents a drop of -46.31%. Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at -109.33%, Pretax Profit Margin comes in at -46.7%, and Net Profit Margin reading is -46.7%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.34 and Total Capital is -0.76. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2767 points at the first support level, and at 0.2647 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.2959, and for the 2nd resistance point, it is at 0.3031.
Ratios To Look Out For
For context, Ovid Therapeutics Inc’s Current Ratio is 5.32. As well, the Quick Ratio is 5.32, while the Cash Ratio is 2.5. Considering the valuation of this stock, the price to sales ratio is 35.98, the price to book ratio is 0.30.
Transactions by insiders
Recent insider trading involved ALEXANDER MARGARET A., President and COO, that happened on Feb 26 ’25 when 5279.0 shares were sold. CBFO, Rona Jeffrey A completed a deal on Feb 26 ’25 to sell 3902.0 shares. Meanwhile, President and COO ALEXANDER MARGARET A. bought 6810.0 shares on Jan 27 ’25.
